Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ocular hypotensive effect of sublingual administration of timolol

Abstract

Purpose: A randomized clinical trial to assess ocular hypotensive effect of sublingual administration of timolol was performed. Patients and methods: Seventeen (9 male, 8 female; age range 45 to 68 years) with bilateral ocular hypertension were selected for the study. Each patient was evaluated with regard to IOP, arterial blood pressure and heart rate before and after each of the following experimental treatment: unilateral ocular administration of 20 μl of 0.5% timolol solution; sublingual administration of 20 μl of 0.5% timolol solution; unilateral ocular administration of 20 μl of saline solution (placebo); sublingual administration of 20 μl of saline solution (placebo). The sequence of the treatments and the eye topically treated were randomly chosen. At least four weeks wash-out elapsed between each experimental treatment. Results: Our results showed that sublingual administration of timolol was able to induce a bilateral significant reduction of the IOP. This reduction was not statistically different from that obtained in the eye treated with timolol. A significantly greater reduction of the IOP was obtained by sublingual timolol than in the contralateral eye after unilateral topical administration of timolol solution. No significant modification of arterial blood pressure and heart rate were evidenced after the treatment. Conclusions: Sublingual administration seems to be a new interesting way for reducing the IOP. Long term studies are required in order to test efficacy and safety of this new treatment.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Nuzzi R, Vercelli A, Finazzo C et al. Studio immunostochimico del tessuto congiuntivale e sottocongiuntivale in pazienti affetti da glaucoma cronico semplice. Boll d'Ocul 1993; 72(2): 305–14.

  2. 2.

    Dixon WJ. BMDP statistical software manual, Release 7.0. Berkley: University of California Press, 1992.

  3. 3.

    Dunham CN, Spaide RF, Dunham G. The contralateral reduction of intraocular pressure by timolol. Br J Ophthalmol 1994; 78: 38–40.

  4. 4.

    Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate. Efficiency and safety. Arch Ophthalmol 1979; 97: 656–8.

  5. 5.

    Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977; 95: 601–4.

  6. 6.

    Zimmerman TJ, Kaufman HE. Timolol. Dose response and duration of action. Arch Ophthalmol 1977; 95: 605–7.

  7. 7.

    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984; 102: 551–3.

  8. 8.

    Alm A, Wickstrom P, Ekstrom C, Ohrman L. The effect of metaprolol on intraocular pressure in glaucoma. Acta Ophthalmol 1979; 57: 236–42.

  9. 9.

    Batchelor ED, O'Day DM, Shand DG, Wood AL. Interaction of topical and oral timolol in glaucoma. Ophthalmology 1979; 86: 60–5.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Quaranta, L., Pasquini, L., Cassamali, M. et al. Ocular hypotensive effect of sublingual administration of timolol. Int Ophthalmol 20, 49–51 (1996). https://doi.org/10.1007/BF00212945

Download citation

Key words

  • hypotensive therapy
  • timolol solution
  • glaucoma